Zavesca has an active substance called miglustat that prevents an enzyme known as glucosylceramide synthase from working. This enzyme is needed in the preliminary phase of the production of glycosphingolipids in the body cells. By halting the enzyme from working, miglustat reduces the production of glycosphingolipids in the cells. This results in slowing down or preventing the development of signs of type-1 Gaucher ailment and to reduce the symptoms of Niemann-Pick type-C sickness.
Drug Name: Zavesca
Generic name: Miglustat